Abesamis Lyn Marielle I, Aliping Evan Gilles A, Armada Fritz Khrystian Gabriel H, Danao Mirriam F, Del Valle Pamela Denise B, Regencia Zypher Jude G, Baja Emmanuel S, Ligsay Antonio D
Department of Biological Sciences, College of Science, University of Santo Tomas, España Blvd., Manila 1008, Philippines.
Department of Clinical Epidemiology, College of Medicine, University of the Philippines-Manila, Pedro Gil Street, Ermita, Manila 1000, Philippines.
Vaccines (Basel). 2022 Aug 5;10(8):1259. doi: 10.3390/vaccines10081259.
Dengue is a viral mosquito-borne disease that rapidly spreads in tropical and subtropical countries, including the Philippines. One of its most distinguishing characteristics is the ability of the Dengue Virus (DENV) to easily surpass the innate responses of the body, thus activating B cells of the adaptive immunity to produce virus-specific antibodies. Moreover, Dengvaxia is the only licensed vaccine for DENV, but recent studies showed that seronegative individuals become prone to increased disease severity and hospitalization. Owing to this limitation of the dengue vaccine, this study determined and compared consensus and unique B cell epitopes among each DENV (1-4) Philippine isolate to identify potential areas of interest for future vaccine studies and therapeutic developments. An in silico-based epitope prediction of forty (40) DENV 1-4 strains, each serotype represented by ten (10) sequences from The National Center for Biotechnology Information (NCBI), was conducted using Kolaskar and Tongaonkar antigenicity, Emini surface accessibility, and Parker hydrophilicity prediction in Immune Epitope Database (IEDB). Results showed that five (5) epitopes were consensus for DENV-1 with no detected unique epitope, one (1) consensus epitope for DENV-2 with two (2) unique epitopes, one (1) consensus epitope for DENV-3 plus two (2) unique epitopes, and two (2) consensus epitopes and one (1) unique epitope for DENV-4. The findings of this study would contribute to determining potential vaccine and diagnostic marker candidates for further research studies and immunological applications against DENV (1-4) Philippine isolates.
登革热是一种由蚊子传播的病毒性疾病，在包括菲律宾在内的热带和亚热带国家迅速传播。其最显著的特征之一是登革热病毒（DENV）能够轻易突破机体的固有免疫反应，从而激活适应性免疫中的B细胞产生病毒特异性抗体。此外，登革热疫苗（Dengvaxia）是唯一获得许可的登革热病毒疫苗，但最近的研究表明，血清阴性个体更容易出现病情加重和住院的情况。由于登革热疫苗存在这一局限性，本研究确定并比较了每种DENV（1 - 4型）菲律宾分离株之间的共有和独特B细胞表位，以确定未来疫苗研究和治疗开发的潜在关注领域。使用免疫表位数据库（IEDB）中的Kolaskar和Tongaonkar抗原性、Emini表面可及性和Parker亲水性预测方法，对来自美国国立生物技术信息中心（NCBI）的40株DENV 1 - 4型毒株（每种血清型由10个序列代表）进行了基于计算机的表位预测。结果显示，DENV - 1有5个共有表位，未检测到独特表位；DENV - 2有1个共有表位和2个独特表位；DENV - 3有1个共有表位和2个独特表位；DENV - 4有2个共有表位和1个独特表位。本研究的结果将有助于确定潜在的疫苗和诊断标志物候选物，用于进一步的研究以及针对DENV（1 - 4型）菲律宾分离株的免疫学应用。
